

Copy number variations in *SMN1* and *SMN2* are associated with the onset and severity of spinal muscular atrophy (SMA), but recent studies have demonstrated that carrier risk and disease severity may also be impacted by the presence of *SMN1* gene duplication variants and a disease modifier variant in *SMN2*, respectively. The AmplideX® SMA Plus Kit* delivers comprehensive results for *SMN1* and *SMN2*, including accurate quantification of exon 7 copy number plus detection of relevant variants and gene hybrids, from a single reaction in less than four hours.

REDUCED COMPLEXITY

- Detection of relevant alterations in a single trace
- AmplideX Reporter Software automates calling and analysis
- Complete kit includes all reagents

OPTIMIZED WORKFLOW

- <4 hrs from DNA to data
- Flexible use on widely installed CE equipment
- Common workflow with AmplideX PCR/CE FMR1* and CFTR* assays eases implementation and training

QUALITY RESULTS


- High concordance with multiple reference methods
- Differentiates between 0, 1, 2, 3 and ≥4 copies for both SMN1 and SMN2
- Robust performance across extraction methods

Amplidex SMA Plus Kit* Workflow - <4 hrs from DNA to Data





A COMPLETE PICTURE FROM A SINGLE TRACE



RELIABLE PERFORMANCE[†]


Excellent Concordance in Independent, Multisite Testing of >460 Samples



High Intralaboratory Precision



Robust Performance Across Extraction Methods



ORDERING INFORMATION

Part Number	Product Description	Number of Reactions
A00055	AmplideX® SMA Plus Kit*	50
A00056	AmplideX® SMA Plus Kit*	100

For more information, please visit asuragen.com

*CE-IVD for U.S. Export Only. †Milligan JN, et al. J Mol Diagn. 2021.

2000-0142 rev B 02/22



Asuragen, Inc. 2150 Woodward Street, Suite 100 Austin TX 78744 www.asuragen.com

